EVOFEM BIOSCIENCE INC - EVFM STOCK NEWS

Evofem Biosciences announces a partnership with Hello Alpha to offer Phexxi, a non-hormonal contraceptive gel, on Hello Alpha's telemedicine platform.

This collaboration aims to enhance women's healthcare by providing hormone-free birth control options, especially for users of GLP-1 medications like Ozempic and Wegovy, which can reduce the effectiveness of oral contraceptives.

This initiative aligns with Hello Alpha's mission to offer accessible and affordable healthcare to women across the U.S.

Phexxi, FDA-approved, is applied before intercourse to maintain a vaginal pH inhospitable to sperm.

Evofem Biosciences (OTCQB: EVFM) has announced the issuance of U.S. Patent No. 11,992,472 by the USPTO. This patent covers the composition and methods for using Phexxi, a hormone-free vaginal gel for contraception. Phexxi, which contains lactic acid, citric acid, and potassium bitartrate, is FDA-approved and works by maintaining a vaginal pH level inhospitable to sperm and certain pathogens. This is the fifth U.S. patent for Phexxi, further solidifying Evofem's intellectual property portfolio. CEO Saundra Pelletier highlighted the importance of this patent in demonstrating Phexxi's innovative approach to hormone-free contraception. Since its U.S. launch in 2020, Phexxi's net sales have consistently grown. Key growth drivers for 2024 include the increasing use of Phexxi for supplemental contraception among women taking GLP-1 agonists, which can reduce the efficacy of oral contraceptives.

On May 15, 2024, Evofem Biosciences (OTCQB: EVFM) reported its financial results for Q1 2024. Key highlights include:

- Received $1M from Aditxt and an additional $2.5M investment by July 1, 2024.

- Strengthened intellectual property with the approval of a new patent for Phexxi.

- Partnered with Modern Remedies to boost Phexxi distribution in the Northeast.

- Renegotiated a 7.4% lower rebate for Phexxi with Medi-Cal, effective July 2024.

Financially, net sales were $3.6M, a 38% decrease from $5.8M in Q1 2023, attributed to cyclical softness and a cyberattack on Change Healthcare. Operating expenses decreased by 31% to $6.4M, leading to a reduced operating loss of $2.8M, a 21% improvement. Despite lower sales, the company expects 2024 to be its fourth consecutive year of net sales growth.

Evofem Biosciences, Inc. strengthens Phexxi's intellectual property with a new composition of matter patent from the USPTO. The patent covers methods of contraception with Phexxi vaginal gel, making it the company's fifth patent in the United States. Phexxi is the first FDA-approved locally-acting contraceptive gel that works without hormones. The product has shown increased net sales since its launch in 2020, with key growth drivers for 2024 including expanded use in women taking oral contraceptives in conjunction with certain drugs.

Evofem Biosciences, Inc. (EVFM) reports third consecutive year of Phexxi net sales growth, with $18.2 million in 2023. Total operating expenses reduced by 64% from 2022 levels. Sales and marketing expense as a percentage of net sales was 54% in Q4 2023, marking significant improvement. The company entered into an agreement to be acquired by Aditxt, Inc. for accelerated growth.

Evofem Biosciences successfully renegotiates Phexxi rebate with Medi-Cal, improving by 7.4% and providing price protection against future increases. The renegotiated rebate will take effect on July 1, 2024, benefiting over 15.4 million beneficiaries in California.

The use of GLP-1 receptor agonists like Ozempic, Wegovy, and Zepbound is increasing rapidly in the US, with over nine million prescriptions written in the last quarter of 2022. These drugs may reduce the effectiveness of oral birth control pills, increasing the risk of unintended pregnancies. Evofem Biosciences, Inc. (EVFM) has recently agreed to be acquired by Aditxt, Inc. (ADTX), aiming to expand its women's health product portfolio.

Evofem Biosciences, Inc. (EVFM) reported strong preliminary unaudited results for fiscal 2023, with record net sales of Phexxi, its hormone-free contraceptive gel, and the lowest total operating expenses since becoming a commercial stage company in 2020. The company achieved net product sales in the range of $18.1 to $18.3 million, an impressive increase compared to 2022, despite a 73% reduction in field force and absence of growth capital. Total operating expenses were reduced by more than 60% from 2022 levels, and the loss from operations improved by more than 75% versus 2022 levels. The CEO attributed the revenue growth to strong consumer demand for Phexxi and the expansion of coverage and reimbursement. Additionally, Evofem entered into a definitive agreement to be acquired by Aditxt, Inc., which is expected to accelerate its growth trajectory into a multi-product women's health franchise.

Evofem Biosciences, Inc. (EVFMD) celebrates the removal of Prior Authorization for Phexxi contraceptive, expanding coverage for 1.8 million Washingtonians across all Medicaid plans. The move coincides with the surge in testosterone levels for fans of the victorious Washington Huskies, following their Sugar Bowl win, and the upcoming 2024 College Football National Championship. Phexxi, the FDA-approved hormone-free contraceptive gel, is now more accessible to women under the Washington State HCA's Managed Medicaid and Fee for Service Medicaid plans, marking a significant milestone for Evofem Biosciences.